Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center Phase I Dose Escalation/Response Trial to Evaluate Safety, Tolerability, and Anti-Tumor Efficacy of Intra-Arterial CBL0137 for Patients With Advanced Extremity Melanoma or Sarcoma

NCT03727789 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT03727789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03727789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center Phase I Dose Escalation/Response Trial to Evaluate Safety, Tolerability, and Anti-Tumor Efficacy of Intra-Arterial CBL0137 for Patients With Advanced Extremity Melanoma or Sarcoma
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1
Overall status
Terminated
Start date
July 1, 2019
Completion date
January 16, 2024
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cutaneous melanoma of the extremity, advanced sarcoma of the extremity, clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, recurrent cutaneous melanoma of the extremity, recurrent sarcoma of the extremity, stage iii soft tissue sarcoma of the trunk and extremities ajcc v8, stage iiia soft tissue sarcoma of the trunk and extremities ajcc v8, stage iiib soft tissue sarcoma of the trunk and extremities ajcc v8, stage iv soft tissue sarcoma of the trunk and extremities ajcc v8